Dedicated to the
Health and Welfare of All Cats
A A A
Font Size
hero-education

Low-molecular-weight heparins: potential treatment for feline heart disease

Jun 17, 2007
icon-blog Winn Funded Research

Alwood, A. J., A. B. Downend, et al. (2007). "Anticoagulant effects of low-molecular-weight heparins in healthy cats." J Vet Intern Med 21(3): 378-387.

Low-molecular-weight heparin (LMWH) has potential benefit in cats at risk for thromboembolic disease, such as cats with severe hypertrophic cardiomyopathy (HCM). However, LMWH pharmacokinetics has not been characterized in the cat. Cats have rapid absorption and elimination kinetics with LMWH therapy. On the basis of pharmacokinetic modeling, cats will require higher dosages and more frequent administration of LMWH to achieve human therapeutic anti-factor Xa activity of 0.5-1 U/mL.

>> PubMed abstract
heparin hcm cat health heart cat cat care hypertrophic cardiomyopathy Winn feline feline health heart failure

More on cat health:

Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Pin with us on Pinterest
Join us on Google+